-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medicine Network December 21st, December 18th, the official website of the State Drug Administration shows that Yangzijiang Pharmaceutical Group's iodized kesha alcohol injection two supplementary applications were approved for evaluation.
addition to the two specifications approved in November, Yangzijiang Pharmaceutical Group's iodized kesha alcohol injections have been evaluated. sales of end-of-life iodized kesha alcohol injections in China's public medical institutions have grown rapidly in recent years, breaking the 3 billion yuan mark in 2019 and falling 4.18 percent year-on-year in the first half of this year, according to
meters of intranet data.
Up to now, iodized kesha alcohol injections have been evaluated by three enterprises, of which Shanghai Stori Pharmaceuticals and Zhengda Tianqing Pharmaceuticals have been approved in 4 categories of imitation, and the same as the evaluation;
On December 18, 2020, the drug approval documents to be received information release data show that iodized keshadol developed by the Norwegian company Nycomed, belongs to a non-ion type iso-permeable djubo contrast agent, water solubility is good, with plasma and other seepage, permeable pressure toxicity is lower than low-permeable contrast agent.
In recent years, China's public medical institutions terminal iodized kesha alcohol injection sales (units: 100 million yuan) Source: China's public medical institutions terminal competition pattern Mienet data show that in recent years, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal iodized keshaol injection sales increased rapidly, in 2019 exceeded the 3 billion yuan mark;
the brand structure, Hengrui Pharmaceuticals has the largest market share, more than 50%, while General Electric and Yangzijiang Pharmaceutical Group ranked second and third, respectively.
Iodine kesha alcohol injection domestic manufacturers source: Mi net one-click search up to now, iodized kesha alcohol injection a total of three enterprises have been evaluated, of which, Shanghai Staili Pharmaceuticals and Zhengda Tianqing Pharmaceuticals two to copy 4 categories of submitted listing applications were approved, and as reviewed;
。